Daniel Gustafson

Professor, Pharmacology & Biomedical Engineering | Director of Research, Flint Animal Cancer Center Clinical Sciences

ACC208 VTH

970-297-1278

About Daniel

Dr. Gustafson is a professor of cancer pharmacology and director of the pharmacology core. He also holds the Shipley University Chair in Comparative Oncology. The Gustafson laboratory focuses on developing therapeutic treatment modalities for cancer with an emphasis on the pharmacology of agents and development of animal, pharmacokinetic, and mathematical model systems that better reflect the clinical progression and pathology of cancer. Current projects include mechanism of action and pharmacology of the MEK inhibitor AZD6244 in human melanoma cell lines and tumor xenografts in mouse models alone and in combination with cytotoxic chemotherapy; drug combinations that target stromal and cancer cells; and pharmacokinetic modeling to describe, simulate and predict effects.

Education

PhD, University of Nevada, Reno, 1992BS, Santa Clara University, 1987

Publications

Diamond, J.R., Bastos, B.R., Hansen, R.J., Gustafson, D.L., Eckhardt, S.G., Kwak, E., Pandya, S.S., Fletcher, G.C., Pitts, T.M., Kulikowski, G.N., Morrow, M., Arnott, J., Bray, M.R., Sidor, C.F., Messersmith, W.A., and Shapiro, G.I. (2010). Phase I safety, pharmacokinetic and pharmacodynamic study of ENMD-2076, a novel angiogenic and aurora kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2010 Dec 3. [Epub ahead of print] PMID 21131552Hudachek, S.F., and Gustafson, D.L. (2010). Population pharmacokinetic analysis of docetaxel using a customized in silico population. J Pharm Sci Aug 27[Epub ahead of print]. PMID 20803616Zhou, Q., Gustafson, D., Nallapareddy, S,.,Diab, S., Leong, S., Lewis, K., Gore L, Messersmith, W.A., Treston, A.M., Eckhardt, S.G., Sidor, C., and Camidge, D.R. (2010). A single center, open label, dose escalation, safety and pharmacokinetic study of ENMD 1198 administered orally to patients with advanced cancer. Invest New Drugs Jan 19 [Epub ahead of print] PMID:20084425Flaig, T.W., Costa, L.J., Gustafson, D.L., Breaker, K., Schultz, M., Crighton, F., Kim, F.J., and Drabkin, H. (2010). Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib. Br J Cancer 103:796-801. PMID 20823888Denton, C.L., and Gustafson, D.L. (2010). Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice. Cancer Chemother Pharmacol Apr 21. [Epub ahead of print]. PMID: 20407895.Flaig, T.W., Glodé, M., Gustafson, D., van Bokhoven, A., Tao, Y., Wilson, S., Su, L-J., Yuan, L., Harrison, G., Agarwal, R., Crawford, E.D., Lucia, M.S., and Pollak, M. (2010). A study of high-dose oral silybin-phytosome followed by prostatectory in patients with localized prostate cancer. Prostate 70:848-855. PMID:20127732.Hansen, R.J., Samber, B.J., and Gustafson, D.L. (2010). Rapid and sensitive LC-MS/MS method for determination of felbamate in mouse plasma and tissues and human plasma. J Chromatog B 2010 Oct 16. [Epub ahead of print]. PMID 21081288Gustafson, D.L., and Thamm, D.H. (2010). Physiologically-based pharmacokinetic modeling to predict doxorubicin pharmacokinetics in dog populations deficient in the ABCB1 drug transporter. J Vet Intern Med 24:579-586. PMID: 20337920Paoloni, M.C., Mazcko, C., Fox, E., Fan, T., Lana, S., Kisseberth, W., Vail, D.M., Nuckolls, K., Osborne, T., Yalkowsy, S., Gustafson, D., Yu, Y., Cao, L., and Khanna, C. (2010). Rapamycin pharmacokinetic and pharmacodynamic relationships in osteosarcoma: a comparative oncology study in dogs. PLoS One 5:e11013. PMID 20543980Quimby, J.M., Gustafson, D.L., Samber, B.J., and Lunn, K.F. (2010). Studies on the pharmacokinetics and pharmacodynamics of mirtazapine in healthy young cats. J Vet Pharmacol Ther 2010 Oct 24 [Epub ahead of print]. PMID 20969604.Thamm, D.H., Kurzman, I.D., Clark, M.A., Ehrhart, E.J., Kraft, S.L., Gustafson, D.L., and Vail, D.M. (2010) Preclinical investigation of PEGylated tumor necrosis factor alpha in dogs with spontaneous tumors: phase-I evaluation. Clin Cancer Res 16:1498-1508 PMID:20160058Wittenburg, L.A., Gustafson, D.L., and Thamm, D.H. (2010) Phase I pharmacokinetic and pharmacodynamic evaluation of combined valproic acid/doxorubicin treatment in dogs with spontaneous cancer. Clin Cancer Res 16:4832-4842. PMID 20705615

                

stdClass Object ( [GetMemberByIdResult] => stdClass Object ( [AddressPrivacy] => 1 [BusinessAddress1] => Veterinary Teaching Hospital - 300 W Drake Rd [BusinessAddress2] => Animal Cancer Center - ACC 226 [BusinessCity] => Fort Collins [BusinessPostalCode] => 80523 [BusinessState] => CO [CSUId] => 0 [DepartmentGroup] => Clinical Sciences Department [DirectoryPrivacy] => [EName] => dgustafs [EmailAddress] => Daniel.Gustafson@ColoState.EDU [EmailPrivacy] => [EmployeeCategory] => Faculty [EmployeeTitle] => Professor, Pharmacology & Biomedical Engineering | Director of Research, Flint Animal Cancer Center [EmployeeType] => Faculty [FirstName] => Daniel [GraduationYear] => [HasMemberCV] => [Id] => 1019 [InternalTitle] => Professor, Pharmacology & Biomedical Engineering | Director of Research, Flint Animal Cancer Center [LastName] => Gustafson [MemberContacts] => stdClass Object ( [MemberContactResponse] => stdClass Object ( [ContactTypeDescription] => Office [Id] => 590 [IsPrimary] => 1 [PhoneNumber] => 970-297-1278 ) ) [MemberDirectoryProfile] => stdClass Object ( [Id] => 711 [ProfileMetaData] => [ProfileText] => Dr. Gustafson is a professor of cancer pharmacology and director of the pharmacology core. He also holds the Shipley University Chair in Comparative Oncology. The Gustafson laboratory focuses on developing therapeutic treatment modalities for cancer with an emphasis on the pharmacology of agents and development of animal, pharmacokinetic, and mathematical model systems that better reflect the clinical progression and pathology of cancer. Current projects include mechanism of action and pharmacology of the MEK inhibitor AZD6244 in human melanoma cell lines and tumor xenografts in mouse models alone and in combination with cytotoxic chemotherapy; drug combinations that target stromal and cancer cells; and pharmacokinetic modeling to describe, simulate and predict effects. ) [MiddleName] => L [NamePrivacy] => [OfficeBldgName] => VTH [OfficeRoomName] => ACC208 [OtherName] => Daniel [PhonePrivacy] => 1 [StudentLevel] => [Website] => ) )